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Objectives. We analyzed qualitative and quantitative data for 98 HIV-negative,
low-risk women in Malawi, Zimbabwe, India, and Thailand who participated in a
safety and acceptability study of BufferGel, a vaginal microbicide to determine
the across-country acceptability of vaginal microbicides among women and their
partners. 
Methods. Quantitative survey data were collected at 7 and 14 days after use
among enrolled women, and exit interviews were conducted with women and
their partners in separate focus group discussions.
Results. Acceptability was high in all sites (73% of women approved of the mi-
crobicide). Women in Africa, where HIV infection rates are highest, were virtually
unanimous in their desire for such a product, suggesting that an individual’s per-
ception of being at risk for HIV will outweigh concerns about side effects, prob-
lems applying a product, or other factors, when products are shown to be effi-
cacious. But men and women reported that use, which was kept secret from an
intimate partner, would be difficult and might “break the trust” of a relationship. 
Conclusions. Acceptability research across diverse settings through all stages
of microbicide research, development, and postlicensure dissemination can help
maximize acceptability and use. (Am J Public Health. 2004;94:1159–1164)
verse, at-risk populations and settings. The
recent increase in phase I clinical trials has
included acceptability research in several
settings.19–27
We report on the acceptability of a micro-
bicide, BufferGel, developed by ReProtect Inc,
Baltimore, Md.28 This odorless and clear gel
with a pH of 3.9 buffers twice its volume of
semen to a pH of approximately 5.0, main-
taining the protective acidity of the vagina
during and after intercourse.28 BufferGel has
no surfactant or detergent properties likely to
cause irritation or clinical lesions. Safety data
have been reported elsewhere,29,30 as well as
acceptability results among low-risk US
women in Rhode Island.19
The study enrolled HIV-negative, low-risk
women in 4 countries—Malawi, Zimbabwe,
India, and Thailand—that have diverse sex-
ual and hygiene practices and varied preva-
lence of HIV and other sexually transmitted
diseases (STDs). Overall acceptability of
BufferGel, self-perceptions of HIV risk, ease/
convenience of use during sex, and potential
for undisclosed use were assessed through
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semistructured interviews and segregated
focus group discussions among women and
among male partners of sexually active
women participants.
METHODS
The study was conducted under the aus-
pices of the National Institutes of Health
(NIH)–funded HIV Network for Prevention
Trials (HIVNET). The protocol team consisted
of in-country investigators at the study sites in
Malawi, Zimbabwe, India, and Thailand; part-
ners at Johns Hopkins University and the Uni-
versity of California at San Francisco; and
staff from Family Health International, the
Fred Hutchinson Cancer Research Center
(FHCRC), and NIH.
Study Design
Participants were asked to apply BufferGel
for 14 days, morning and evening, and to
wash and dry the applicator after use.
Women in the sexually abstinent cohort were
requested to refrain from sexual activity for
In the United States and throughout the
world, women represent the largest percent-
age of newly infected HIV-positive individu-
als,1,2 yet in many settings their ability to pro-
tect themselves is limited. The effectiveness
and use of male and female condoms are lim-
ited by the need for women to negotiate for
use with their sexual partners.3 Microbicide
products that women could electively use, in-
stead of depending on male use of condoms,
hold great promise for HIV prevention, par-
ticularly among women who perceive them-
selves to be at high risk of infection.4
More than 60 candidate products are cur-
rently in various stages of development, and
17 have reached the stage of clinical testing
to determine safety, efficacy, and acceptabil-
ity.5,6 The Rockefeller Foundation Microbicide
Initiative defines acceptability as a woman’s
willingness and ability to use a product or
technology in everyday life; it includes her
perception of risk and her concerns about or
experiences with side effects, alternative prod-
ucts, behavioral choices, cost, and access.
Data regarding such perceptions and con-
cerns are needed to identify factors that facili-
tate or discourage effective microbicide use in
diverse settings.7
Because approved microbicides are not
available, most acceptability research has re-
lied on indirect study designs. Some studies
have surveyed potential users about desirable
and undesirable product attributes; others
have solicited reactions to existing products of
similar design, such as spermicides by high-
risk women and men individually and in cou-
ples.8,9–17 Recently, some investigators have
called attention to social context, as well as
physical and clinical attributes of products,
with regard to acceptability.18
Conducting microbicide acceptability re-
search during clinical trials permits us to as-
sess factors that pertain to actual products
being developed for marketing among di-
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TABLE 1—Participant Responses Regarding Product Features Among Sexually Active Women
at Day 14, by Site
No. Responses (%)
Malawi Zimbabwe India Thailand Total
Total 22 25 21 24 92
If approved, would you use BufferGel?
Yes 20 (91%) 25 (100%) 7 (33%) 15 (63%) 67 (73%)
In some circumstances 2 (9%) 0 3 (14%) 9 (38%) 14 (15%)
No 0 0 11 (52%) 0 11 (12%)
Total 22 25 20 24 91
BufferGel features liked “a lot” or “somewhat”:
Ease of insertion 22 (100%) 24 (96%) 18 (90%) 20 (83%) 84 (92%)
Reusable applicator 18 (82%) 19 (76%) 13 (65%) 10 (42%) 60 (66%)
Color 22 (100%) 24 (96%) 16 (80%) 23 (96%) 85 (93%)
Smell 20 (91%) 23 (92%) 10 (50%) 21 (88%) 74 (81%)
At least sometimes, the product:
Felt too wet or drippy 10 (45%) 12 (48%) 13 (65%) 10 (42%) 45 (49%)
Soiled clothes 9 (41%) 7 (28%) 2 (10%) 10 (42%) 28 (31%)
the duration of the study. Sexually active
women were asked to have sex at least twice
a week and to use study-provided nonlubri-
cated condoms during all acts of vaginal inter-
course during the study period. Women
agreed not to douche or clean their vaginas
or to apply any other products to their vagi-
nas during the study.
Following the study design and methods
used in the Rhode Island safety and accept-
ability study,19,29,30 we collected acceptability
data for the international sites, using struc-
tured interviews and focus groups with men
and women. All social scientists and data col-
lectors participated in regional training in
Africa and Asia to ensure standardization of
methods.
During clinic visits at days 7 and 14, an in-
terviewer administered a questionnaire on
product characteristics (e.g., smell, color, tex-
ture) and applicator characteristics (e.g. porta-
bility, ease of use, comfort, cleaning). Women
in the sexually active cohort were asked
about partners’ reaction to the product and
use of the product during sex. At day 14, all
study participants answered questions about
their willingness to use the product or rea-
sons for being unwilling to use the product if
it were approved. After completing the trial,
women and their male partners were invited
to join gender-specific focus group discus-
sions. The focus group data were collected to
provide context and meaning to the quantita-
tive survey data.
Study Participants
Sexually active and sexually abstinent co-
horts were recruited from patients visiting
Queen Elizabeth Hospital, Blantyre, Malawi;
Spilhaus Clinic, Harare, Zimbabwe; and
Jahengeer Clinic, Pune, India; and from staff
at Chiang Mai University, Chiang Mai, Thai-
land. Participants were HIV negative, had no
history of STDs in the past 6 months, and
were either sexually abstinent or in a stable,
monogamous relationship. Inclusion and ex-
clusion criteria have been described previ-
ously.29,30 Written informed consent was ob-
tained from all participants before any
clinical examinations or questionnaires were
administered.
Between July 1998 and April 1999, 288
women were screened, and 98 were enrolled
in the study (30 sexually abstinent, 68 sexu-
ally active). The average age was 33 years
(range: 18 to 44 years). Most women had
completed either primary (44%) or some sec-
ondary (47%) school and were either unem-
ployed (46%) or employed full-time (42%).
Most abstinent (57%) and all sexually active
women were married. Three women were
dropped from the study because of a diagno-
sis of Candida at the day 7 visit; 2 left be-
cause of breakthrough menstrual bleeding;
and 1 woman was not able to meet the prod-
uct use adherence criterion of application on
at least 12 of 14 days and elected not to con-
tinue. Of the 98 women who completed the
study, 85 (93%) met the product use adher-
ence criterion. Transcripts from 17 focus
group discussions with 99 people were ana-
lyzed (at least 1 group for each women’s co-
hort and 1 men’s group from each country).
Data Analysis
Structured questionnaire data were entered
with Microsoft Access 199732 at the 4 inter-
national sites, transferred electronically to
FHCRC, and converted into SAS database
files.32 FHCRC statisticians resolved data
queries with data managers at each site. De-
scriptive data were stratified by country and,
when applicable, by cohort (sexually abstinent
or sexually active). Small cell sizes precluded
the use of statistical tests. The primary study
endpoint (outcome indicator) for acceptability
was the proportion of women who reported at
the end of the study that they would be will-
ing to use BufferGel if it were approved for
vaginal application.
FDGs were taped, transcribed, and im-
ported into Nud*ist 433 for analysis, and a
data matrix and display approach was used.
Researchers read all transcripts to identify
and code themes used by Nud*ist 4 to gener-
ate reports of like-coded blocks of text. Text
blocks associated with codes were analyzed
for dimensions of attitude, perspective, and
association with other codes. For central
themes, data matrices were used to examine
differences by country, gender, and cohort.
RESULTS
Overall Acceptability
Based on structured interview data, all
women in the African sites and most (57%
abstinent, 65% sexually active) women in
Thailand said that they would use the prod-
uct if approved, compared with much smaller
proportions (17% and 60%, respectively) of
women in India (Table 1). Men and women in
African focus group discussions overwhelm-
ingly expressed a need for protection from
HIV and welcomed the possibility of having
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new products available that could prevent
HIV transmission. By contrast, women in In-
dian focus group discussions who said that
they would not use BufferGel believed that
they were not at risk of HIV infection and did
not need a protective method.
Perception of Risk
HIV risk perception was not assessed quan-
titatively. However, most groups in Zimbabwe
and Malawi discussed HIV risk at some
length in association with sexual risk. A
Malawian woman said “I can indeed control
my desires for sex and be faithful to my part-
ner, but this may not be the same with him.
I can’t monitor his movements. . . .” Some
men acknowledged that their own wives
might use the gel, saying “Considering the
warnings that she had been giving me [about
being unfaithful], it made me happy that she
could use it [the gel],” or, “If you know that
you are promiscuous, you have to say that
you want to use BufferGel with [your] wife,
because you know that you may bring her
the virus and give it to her.” Other African
men worried that encouraging one’s wife to
use a microbicide would cause her to become
promiscuous. One man questioned whether
the product should be made available at all,
whereas several others said that it should be
used only by “these other women who do not
have a man they call their own. . . .” Another
man proposed selling the gel only to men: “If
I want to be promiscuous, I can just take this
product and give it to my partner. It shouldn’t
be sold to women, because they will just use
it to have sex with other men.” 
Women in Africa worried about HIV af-
fecting the next generation. A Zimbabwean
woman commented “We have children who
are growing up. They should stay alive. We
are scared for them.” Some Thai women also
stated that they felt themselves to be at risk
for HIV and envisioned using a product like
BufferGel in the future, should it be proven
effective. Indian women seemed to distance
themselves from personal vulnerability; in
their discussions of potential future use of
BufferGel, they tended to focus on hypotheti-
cal promiscuous women: “Only women who
are like that—women who go out, keep out-
side relations with many men . . . the other
women have no reason to use this medicine.”
Undisclosed Use
In focus group discussions, few women or
men considered undisclosed use to be feasi-
ble, given the product’s characteristics. Prop-
erties of the gel that would make undisclosed
product use difficult included increased wet-
ness, stickiness, or telltale signs on men’s
penises or on condoms. A man from Zim-
babwe suggests that the gel cannot be used
clandestinely, stating that men might “feel
that something [is different]. . . . Why did it
get wet so quickly? What is it? . . . So, you
would ask what is happening?” However, to
avoid a partner’s discovery, one Zimbabwean
woman said, “you use half as much but insert
deeply—and if the partner asks, just tell him it
is normal vaginal discharge. He won’t know
exactly what it is.” Some women were not
sure that they would be able to apply the
product privately before intercourse.
Whether feasible or not, undisclosed use
also was viewed as undesirable and poten-
tially risky. African men and women ex-
plained in focus group discussions that undis-
closed use would be inappropriate “because
we are one body” or “we are one when we
are in this house.” Possible adverse outcomes
of a wife’s undisclosed use, if such use is de-
tected, included disagreement in the home,
being sent to one’s parents’ house, physical vi-
olence, or even divorce. Zimbabwean women
anticipated a need to attribute their use of
such a product to health concerns that would
not impugn their partners’ sexual fidelity: “It
is better to be honest with him that you are
using BufferGel to protect yourself from dif-
ferent infections. Even if you know that it is
for preventing HIV, you just tell him that it is
protecting you from cancer or other gynecol-
ogical problems.” One woman in the sexually
abstinent cohort in Zimbabwe observed that
“single women have the right to tell [the man]
‘I am using this, whether you like it or not.’
It’s different for a married woman, who might
be sent packing if she does that.”
Ease of Insertion and Applicator
Features
Almost all participants (92%) found the ap-
plicator easy to insert; 31% of women dis-
liked having to clean and reuse it (Table 1). In
focus group discussions, concerns about
cleaning offset ease of insertion in women’s
overall appraisal, especially among women
who did not have access to running water or
feared loss of privacy when using a commu-
nal tap. A woman from Malawi worried about
leaving it out to dry if droplets “could result
in other infections, and you would think it’s
the gel [that caused the infection, when] it’s
the applicator.” A Thai woman tried to disin-
fect the applicator with alcohol, although not
instructed to do so, and experienced burning
sensations on using it. Indian and Thai
women worried about storing the gel and ap-
plicator away from children who might play
with the items or ask questions. Single-dose
disposable applicators and tablet or supposi-
tory delivery systems were suggested as alter-
natives, but these suggestions did not entirely
resolve storage concerns and evoked ques-
tions about cost.
Responses to BufferGel’s Physical
Characteristics
Women liked many characteristics of
BufferGel (Tables 1 and 2), in particular that
it is colorless (94%) and odorless (81%). In
focus groups discussions, a few participants
compared BufferGel’s color to that of
women’s natural discharge: “similar to the
fluid that women discharge from their body,”
as a Zimbabwean man expressed it. The ma-
jority of Indian women in the abstinent co-
hort said that the product’s lack of odor was
advantageous “because no one can make out
that it has been used.” In Zimbabwe focus
group discussions, 1 man and several women
suggested that using the gel could help
women prevent odor. A woman from Malawi
said that the lack of odor “means that the gel
is a strong drug.” A few men from Thailand
and Zimbabwe requested that a deodorant or
nice scent be added to the gel. According to
survey data, less than half of women (49%)
had some concerns related to the gel’s consis-
tency, especially wetness or drippiness
(Table 1). In focus group discussions with sex-
ually active women, a few Africans and the
majority of Indians and Thais found the gel
too thin, slippery, or prone to leaking, some-
times comparing it to the slow trickling that a
woman experiences during her menstrual pe-
riod. Leakage caused 31% of women to re-
port that BufferGel soiled their clothes
(Table 1). Some managed to mitigate this
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TABLE 2—Participant Responses Regarding Product Characteristics Among Sexually Active
Women at Day 14, by Site
No. Responses (%)
Malawi Zimbabwe India Thailand Total
(n = 16) (n = 17) (n = 15) (n = 17) (n = 65)
Strongly or somewhat liked the way BufferGel felt 15 (94%) 17 (100%) 12 (80%) 10 (59%) 54 (83%)
Product never or rarely leaked out:
Prior to sexual intercourse 15 (94%) 15 (88%) 15 (100%) 15 (88%) 60 (92%)
During sexual intercourse 10 (63%) 16 (94%) 9 (60%) 11 (65%) 46 (71%)
After sexual intercourse 14 (88%) 13 (76%) 11 (73%) 13 (76%) 51 (78%)
At least somewhat agreed that product interrupted:
Own sexual pleasure 4 (25%) 4 (24%) 2 (13%) 4 (24%) 14 (22%)
Partner’s sexual pleasure 7 (44%) 3 (18%) 2 (13%) 3 (18%) 15 (23%)
At least somewhat agreed that product added to:
Own sexual pleasure 6 (38%) 13 (76%) 8 (53%) 6 (35%) 33 (51%)
Partner’s sexual pleasure 4 (25%) 13 (76%) 6 (40%) 5 (29%) 28 (43%)
Strongly or somewhat agreed that they had more 1 (6%) 2 (12%) 2 (13%) 11 (65%) 16 (25%)
communication problems than before the study
leakage with pads or cotton wool provided by
the study. Other women recommended
changing BufferGel so that it was not so liq-
uid or suggested that it could be formulated
to be effective in smaller volumes or reformu-
lated as a suppository.
Nevertheless, the majority of sexually ac-
tive women participants (83%) liked how the
product felt (Table 2). Only a few reported
significant product leakage before (8%), dur-
ing (29%), or after (22%) sex (Table 2). One
Zimbabwean man commented “I don’t de-
spise it, although there were some problems
such as it being messy. . . . We can’t say it was
too messy. It was just like she was having her
periods, you see. It is something that can be
washed.” A couple of men from Zimbabwe
reported that this wetness kept them from
wanting to touch their partner during sexual
foreplay. Some women said that the product
was not leaky if it was inserted deeply
enough or if the woman waited sufficient
time after insertion to have sex.
Several Thai men and one man from Zim-
babwe disliked the sticky nature of the gel, al-
though other men and women found this at-
tribute desirable. As explained by a Malawian
woman, “BufferGel had a tightening effect and
it was not slippery, so I was happy with the
product.” Another woman from Zimbabwe
said: “We did not have any wetness problems,
because BufferGel used to sort of dry up and
stick. So, it was not slippery. It was perfect.” In
fact, approximately half of the women from
the Zimbabwe sexually active focus group dis-
cussion said that the consistency of BufferGel
made “sex nicer than on normal days.” They
explained that dry sex is painful and prolongs
the sexual episode: “With BufferGel it is not
slippery. It is actually nicely sticky.” The per-
ception that the product enhanced sexual
pleasure also was reflected in survey data; ap-
proximately half of women reported that their
own (51%) or their partner’s (43%) sexual
pleasure was increased (Table 2).
Perceived Side Effects
Some women and men in almost all focus
group discussions indicated that they had an-
ticipated side effects, believing, for example,
“that I was going to be given harmful prod-
ucts that would burn my vagina.” Several In-
dian women chose to participate in the absti-
nent cohort to protect their husband’s health.
An Indian woman in the sexually active co-
hort said: “All the time we were wondering
whether anything would happen to me or my
husband. So, sex was dissatisfying.” One Zim-
babwean man worried about whether the gel
“would affect me or my penis, that it would
make me sick or something would happen.”
Another “was afraid that if I remove the con-
dom and have sex without one, it might affect
me.” Most participants expressed surprise and
satisfaction that the gel did not cause the
problems they anticipated. One Zimbabwean
woman, for example, said, “On the first day, I
was surprised because I did not feel anything.
I just felt like I did before [using the gel].”
DISCUSSION
Employing the same protocol and method-
ology previously used among low-risk women
in Rhode Island19 in this multisite study in 4
less-developed countries, we found that over-
all acceptability of BufferGel was high and
that women were unanimous in their belief
that such products should be available to
women if proven to be safe and effective. The
womens’ perceptions of being at risk and the
stage of the HIV epidemic within each setting
placed the results in context for the research-
ers; in settings in which the HIV epidemic is
more advanced (particularly in Zimbabwe
and Malawi) and women therefore presum-
ably perceived their risk to be high, accept-
ability was unanimous.
Across all settings, but particularly in the
African sites, both men and women were con-
cerned about not communicating with their
partners about using such products. Focus
group participants, particularly those from the
African sites, concentrated on issues related
to partner trust and the dangers—including vi-
olence—of undisclosed use in marriages or es-
tablished relationships. Most participants ex-
pressed that even if a product could be used
during sex without alerting the partner, it was
important for couples to make the decision
jointly to use the product. BufferGel’s wetness
and its appearance on the man’s penis would
alert men that a woman had inserted some-
thing into her vagina before sex. Men from all
sites believed that they had the right to partic-
ipate with their wives in discussing the use of
microbicides. However, this discussion might
raise questions about the fidelity of either or
both partners, depending on which partner
introduced the topic and how the rationale
was presented. Some men acknowledged that
microbicides would be an important option
for “other” women—those without a husband
or a regular partner or those who are
“promiscuous.” The availability of microbicide
products may threaten some men’s perception
of their control of women. Some women in
July 2004, Vol 94, No. 7 | American Journal of Public Health Bentley et al. | Peer Reviewed | Research and Practice | 1163
 RESEARCH AND PRACTICE 
the study anticipated this problem and sug-
gested portraying microbicides as generic
vaginal health products when describing their
reasons for using them to a male partner.
It will be important, therefore, to antici-
pate men’s concerns and to develop strate-
gies for promoting microbicides among sta-
ble partners and in marital relationships.
Upon microbicide products’ becoming avail-
able in the marketplace, site-specific and
subgroup-specific acceptability and market-
ing research can continue to address these
issues as the populations increase in risk and
cultural diversity. Women at higher risk
might devise solutions for maintaining pri-
vacy or secrecy of use, but including men in
acceptability and marketing research helps
to clarify men’s major concerns and identify
strategies that may effectively preempt or
address these concerns. In general, men in
this study appeared to be responsive to the
need for women to protect themselves. With
expanded trials, acceptability research
should include community opinion leaders
and authorities whose views may affect fu-
ture dissemination of effective products.
This study had a number of limitations.
First, a phase I trial requires the enrollment of
women who are at low risk for STDs/HIV, a
population not representative of the women
at highest risk for infection, whose approval
of a microbicide product could be even
stronger than that in our study. Second, the
trial required condom use during all sexual
acts; we did not study BufferGel’s acceptabil-
ity during unprotected sex, when presumably
microbicide use would be of greatest benefit.
Twice-daily use is at the upper limit of the
dose most women would require; therefore,
issues related to messiness would likely be di-
minished for most users. It is difficult to con-
clude from 2 weeks’ use of an investigational
product of unknown efficacy whether practi-
cal problems would became more trouble-
some after sustained use by high-risk women
or would be resolved. For example, soiling
of clothes was addressed by the use of ab-
sorbent pads. This solution might become ei-
ther an acceptable routine or a recurring an-
noyance. Concerns about cleaning a reusable
applicator are being addressed by packaging
gels in single-use disposable applicators, but
storage may be a consideration for either ap-
proach, as well as privacy.
Our data suggest that negative perceptions
regarding product characteristics (wetness,
drippiness, stickiness) should be identified in
microbicide acceptability research. However,
users’ perception of infection risk may out-
weigh these “nuisance factors” once microbi-
cide products are proven efficacious, as we
previously found in the Rhode Island trial.19
Larger trials among higher-risk women will
provide an opportunity to investigate and ad-
dress issues related to applicator characteris-
tics, privacy, cleaning, and storage in diverse
geographic, demographic, and sociocultural
settings.
Microbicide acceptability research can con-
tribute to product development and to mes-
sages used for introducing such products be-
fore specific products are proven efficacious
for HIV prevention. Acceptability research
through postlicensure dissemination can facili-
tate maximum access to products among
those populations most in need of additional
preventive technologies. This research should
include social and contextual research into
gender relations, sexuality, and sexual behav-
ior to establish the context within which these
products will be promoted and used.34
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